Abstract
The
therapeutic window for acute ischemic stroke with intravenous
recombinant tissue plasminogen activator (IV rt-PA) is brief and
crucial. The American Heart Association/American Stroke Association
Target: Stroke Best Practice Strategies (TSBPS) aim to improve
intravenous thrombolysis door-to-needle (DTN) time. We assessed the
efficacy of implementation of selected TSBPS to reduce DTN time in a
large tertiary care hospital. A multidisciplinary DTN committee assessed
causes of delayed DTN time and implemented focused TSBPS in our urban
academic medical center. We analyzed door-to-CT time, DTN time, and CT
to IV rt-PA time in consecutive patients treated with IV rt-PA over 27
months preimplementation and 13 months postimplementation. One hundred
forty-eight patients were included in the preimplementation and 126 in
the postimplementation group. We found no significant difference between
the groups in demographics, comorbidities, anticoagulation status,
prethrombolysis hypertension treatment, arrival by EMS, after-hours
arrival, or in stroke etiology. After implementation, median DTN time
improved from 59 (interquartile range [IQR]: 52-80) to 29 (IQR: 20-41)
minutes (P < .001). Door-to-CT time decreased from 17 (14-21) to 16 (12-19) minutes (P = .016), and CT-to-IV rt-PA time improved from 43 (IQR: 31-59) to 13 (IQR: 6-23) minutes (P < .001). Rates of symptomatic intracranial hemorrhage (2.7% vs 3.2%, P = .82) and treatment of stroke mimics (9% vs 13%, P
= .31) were similar in both the groups. Individualized hospital gap
analysis identifies targeted interventions that lead to rapid and
sustained improvement in treatment times.
No comments:
Post a Comment